• Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020
• CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers
• Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members, Dr. Waldemar Priebe, Ph.D., and Dr. Sigmund Hsu, M.D., both of whom were involved in the Phase 1 trial of Berubicin, CNS Pharmaceuticals’ lead drug candidate.

Dr. Wen is a Neurology professor at Harvard Medical School and the Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. Dr. Wen is a member of the Board of Directors of The Society for Neuro-Oncology and is also its immediate past President. An accomplished neuro-oncologist with a proven track record treating brain tumors and related neurologic complications, Dr. Wen is a graduate of University of London’s Medical College of St. Bartholomew’s Hospital. He continued his postgraduate internal medicine training with the University of London and completed his neurology residency with the Harvard-Longwood Neurology Training Program.

According to CNS Pharmaceuticals CEO John Climaco, Dr. Wen’s extensive experience in neuro-oncology will be invaluable to the company as it prepares for its upcoming Berubicin clinical trials. “The addition of Dr. Wen strongly complements our strategy to further drive the development of Berubicin as we look forward to initiating our pivotal Phase II trial in the U.S. and to working with our partner WPD Pharmaceuticals on the Phase I pediatric and Phase II adult studies in Poland,” Climaco added.

Dr. Wen’s appointment was included among the latest company updates furnished to the Securities and Exchange Commission on September 21, 2020. The investor presentation in the Form 8-K/A also announced that the company’s pivotal Phase 2 clinical trial for Berubicin in the United States is expected to begin in Q1 2021 (https://ibn.fm/MRaIq). In addition, Berubicin clinical trials in Poland (Phase 2 for adults and the first-ever Phase 1 trial for pediatric patients) are also due to begin on a similar timeline.

CNS Pharmaceuticals’ lead drug candidate is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. It is an organ targeted therapeutic that belongs to a class of cancer drugs called anthracyclines. CNS Pharmaceuticals has stated that it believes, based on limited clinical data, that Berubicin is the first drug in this class to cross the blood-brain barrier in adults, reaching the tumor cells of a patient with brain cancer.

Berubicin was developed by CNS Founder and Scientific Advisory Board member Dr. Waldemar Priebe, Ph.D., Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The development of Berubicin has been ongoing for over 15 years. The drug was granted Orphan Drug designation by the FDA for malignant gliomas in June 2020. CNS Pharmaceuticals is currently expected to make an Investigational New Drug (“IND”) submission to the FDA in Q4 2020.

In Phase 1 trials of Berubicin, conducted by Reata Pharmaceuticals (NASDAQ: RETA), 44% of GBM patients showed clinically significant response to Berubicin. A patient from the Phase 1 trial remains cancer-free following the trial treatment of Berubicin approximately 14 years ago.

CNS Pharmaceuticals plans for the Phase 2 adult trial in the United States to be adaptive, randomized, and controlled. These criteria for Phase 2 are intended to provide the data required for accelerated approval by the FDA. Additionally, the company plans to use the Phase 2 adult trial in Poland, conducted by sub-licensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1), to provide additional statistical support for the U.S. trial.

Plans are also in motion to begin Berubicin clinical trials for lymphomas, pancreatic, and ovarian cancers in 2021, which speaks to the high level of confidence CNS Pharmaceuticals has in Berubicin trials and its potential impact on the brain tumor therapeutics market. It is estimated that the global brain tumor therapeutics market will reach $3.4 billion by 2025, growing at a CAGR of 7.2 percent (https://ibn.fm/fqDvu).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• SRAX recently closed acquisition of LD Micro, leading micro-cap information portal
• LD Micro to become wholly-owned subsidiary of SRAX for 1.6 million in common stock plus $4 million cash
• Acquisition to accelerate adoption of Sequire, SRAX’s SaaS investment analytics platform
• Sequire revenue grew 29% year-over-year for Q2 2020, user base doubled to one million users during Q3 2020

SRAX (NASDAQ: SRAX), a data-based financial technology company, recently closed the acquisition of LD Micro, a leading data portal serving the small and micro-cap space. The deal, worth 1,600,000 shares of common stock and $4 million in cash, will make LD Micro a wholly-owned subsidiary of SRAX while maintaining founder Christopher Lahiji as president and appointing him to SRAX’s board of directors. The move comes during a rapid growth period for Sequire, SRAX’s data analytics SaaS platform. Geared towards the investment industry, Sequire unlocks data and insight for public companies that can be used to activate marketing campaigns to engage both new, existing and potential investors. Prior to acquiring LD Micro, SRAX had witnessed strong early success with Sequire. The platform doubled its user base to over one million investors and traders in two months (https://ibn.fm/j6oNa), in addition to posting Q2 earnings that showed a 29% increase in year-over-year revenue. The acquisition of LD Micro – a leading brand in the provision of exclusive information on micro-cap North American stocks – is expected to accelerate the adoption of Sequire while enhancing LD Micro’s own digital assets. Sequire helps public companies gain insights on the activities of both retail and institutional investors, providing critical actionable data to activate successful campaigns aimed to increase engagement with current investors while attracting new ones. Sequire’s application suite is currently being used by over 91 companies to harness the power of their data through the use of tools that leverage investor intelligence and outreach, track warrants, engage users through surveys, and promote events and roadshows. “The platform is an absolute game-changer for public companies and their shareholders,” said LD Micro founder Chris Lahiji in recent statements (https://ibn.fm/Mzz1z). “Both companies believe that one day executives will rely on Sequire the same way investors rely on Bloomberg.” “Over 1,500 companies have presented at LD Micro’s events since 2008, and almost all of them would be immediate beneficiaries of this technology,” he continued. The acquisition of LD Micro is expected to be immediately accreditive to SRAX’s operations. The recent LD 500 conference, held online in early September, included presentations from hundreds of companies across a wide range of industries in addition to featuring keynotes with some of the most prominent figures in the micro-cap world. The company continues to leverage the growing demand for quantifiable and detailed consumer data by creating specialized tools that empower companies to reveal core consumers and their characteristics across a wide range of industries. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Partnership allows space for significant exposure, growth over critical launch period
• AffPapa’s dedication to mission provides opportunities to broaden operator base, offer best services
• Mobius has already entered iGaming, eSports sectors with three differentiated brand offerings and hundreds of joint ventures with VIP and Master gaming affiliates

Mobius Interactive has announced a new partnership with AffPapa, a unique platform that allows operators and affiliates to find each other. In a recent announcement, Mobius and AffPapa noted the “well-timed collaboration” designed to ease the process of finding partners and overcome challenges (https://ibn.fm/AYlFm).

“By joining our affiliate site with the AffPapa global affiliate and operator partnership platform, MobiusAffiliates.com will be a valuable addition to its affiliate directory, allowing space for significant exposure and growth over its critical launch period,” said Mobius CEO Lynn Pearce.

“AffPapa has picked up its pace, venturing into new projects and developing our strategic objectives,” said AffPapa CEO Chris Chandler of the collaboration. “We at AffPapa think it’s the dedication to our mission that provides opportunities to broaden our operator base and continue offering the best services. I’m looking forward to a successful partnership.”

With the help of flexible filters, AffPapa helps each party search for the most relevant partner and find the best match within minutes. Both parties are gathered under one roof with the aim to ease the process of finding partners and overcome all impediments.

Looking forward to an official launch soon, Mobius has already entered the iGaming and eSports sector with three differentiated brand offerings and joint ventures with more than 600 VIP and Master gaming affiliates. The company’s management team has led the launch of more than 30 successful products within the last three years, and its partnership with UltraPlay is a key factor in this month’s kickoff.

Through UltraPlay, Mobius currently offers more than 34 unique games and sports betting available 24/7. Mobius’ sports betting product has a wide range of functionalities; it also offers mystery jackpots, cutting-edge tech and live and pre-match odds. In addition, the company’s live casino games are compatible with desktop, smartphone, laptop and tablet devices and can accommodate any number of players at any time.

Mobius Interactive is an online gaming operator featuring a variety of unique offerings catering to diverse demographic groups. Mobius Interactive’s team has extensive senior-management experience across business-to-consumer (“B2C”) and business-to-business (“B2B”) marketing in the iGaming industry, specializing in eSports, sports betting, casino and live casino. In partnership with leading and award-winning eSports and iGaming platform Ultra Play, Mobius Interactive seeks to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance engagement by leveraging state-of-the-art customer relationship management systems and joint ventures with more than 600 VIP and master-gaming affiliates.

For more information, visit the company’s website at www.MobiusInteractive.Ltd.

NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Company awarded government grant that could total $1.45 million to develop design for production of rare earth elements
• UUUU excited to play role in effort to develop domestic sources of rare earth production
• Energy Fuels announced entry into REE sector earlier this year, ideal complement to company’s other rare earth initiatives

Energy Fuels (TSX: EFR) (NYSE American: UUUU), a leading producer of uranium in the United States, along with a team from Penn State University has been awarded a government grant for an initial amount of $150,000 to develop a design for the production of rare earth elements (“REE”) from coal-based resources (https://ibn.fm/kMbwJ). The contract was awarded by the U.S. Department of Energy (“DOE”) Office of Fossil Energy (“FE”) and the National Energy Technology Laboratory (“NETL”). If Energy Fuels is successful at the conceptual design phase, the DOE could award Energy Fuels an additional $1.3 million to complete a feasibility study.

“We are excited to have the opportunity to work with the DOE office of Fossil Energy, the National Energy Technology Laboratory, and Penn State on this important rare earth initiative,” said Energy Fuels president and CEO Mark S. Chalmers. “Energy Fuels has been carrying out substantial work over the past year to explore the potential for implementing a commercial rare earth recovery and processing program at our White Mesa Mill. This initiative to produce REOs from coal-based resources is complementary to our ongoing efforts and will potentially broaden the sources of REE feedstock available to us in the future. We also hope this project opens the door for us to work with the DOE and other agencies on future rare earth initiatives.”

The contract calls for Energy Fuels and a team of experts from Penn State to evaluate and develop a conceptual design to allow for the commercial production of mixed rare earth oxides from coal-based resources in an environmentally benign fashion. In addition, the contract also notes that DOE may award Energy Fuels a contract for the completion of a feasibility study on this initiative.

The DOE has already demonstrated the technical feasibility of extracting rare earth elements from coal and coal-based resources, but the department is looking to fast-track the advancement of commercially viable technologies to produce REEs from coal-based resources, including coal refuse, over/under burden materials, power generation ash and others.

Earlier this year, Energy Fuels announced its entry into the REE sector, noting that it believes its fully licensed and constructed White Mesa Mill could play a key role in bringing the REE supply chain back to the U.S. from China (https://ibn.fm/UEB25). The company applied for the DOE/NETL grant in June, in part because the REE minerals contained in these coal-based resources are similar to the REE minerals contained in other materials UUUU is evaluating as part of its REE program.

The contract provides initial funding for Energy Fuels and the Penn State team to complete a detailed conceptual design and flowsheet for the possible commercial operation of a facility that produces REOs from coal-based resources. Once that is complete, the DOE will determine whether to provide additional funding for the development of a feasibility study. It is also possible that the DOE could participate in the funding of a facility that performs this work.

“Rare earths are used in a host of advanced and everyday technologies, including cell phones, computers, renewable energy generation, batteries, automobiles, and military applications,” said Chalmers. “However, the U.S. does not currently have a fully integrated rare earth supply chain. Therefore, the government has made it a priority to assist in the development of domestic sources of rare earth production. With this award, we are excited to play a role in this effort, while also pursuing our other complementary rare earth initiatives. We also hope this DOE program puts Energy Fuels on the radar for other U.S. government rare earth initiatives.”

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (ISR) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah – the only conventional uranium mill operating in the United States today. Together, these facilities have a licensed capacity of more than 11.5 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era of viable transformation of the U.S. nuclear industry.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• BFGC lays out road map to success
• Potential of area highlighted as majors show interest
• Drill results encourage further exploration
• Gold price maintains lofty levels

The virtual investor presentation given by Bullfrog Gold (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) at the Aug. 6 OTCQB Virtual Investor Conference laid out BFGC’s well-thought-out road map to becoming a profitable gold producer. Bullfrog was one of several companies carefully selected to present to individual and institutional investors, advisors and analysts attending the event.

Starting with a brief account of BFGC’s earliest acquisitions, CEO David Beling went on to show the exciting potential the Bullfrog Mining District of Nevada, location of the company’s properties, has. He also discussed the company’s current drilling program, which has returned promising results. With gold prices at the level they are now — above $1,900 an ounce —Bullfrog seems to be in the right business at the right time.

The presentation noted that the company started trading in the year 2011 and it acquired a strategic land position adjacent to Barrick Bullfrog Inc. in Nevada’s Bullfrog Mining District (the District).  Now, the company has commanding land and resource positions in an area that has, in the past, proved highly productive and is surrounded by several major land holders successfully exploring in one of the most prolific gold exploration areas in the US

Beling also explains that Bullfrog’s property positions lie about four miles to the west of Beatty, a town of about 1,000, in Nevada. The Bullfrog area is well-developed for industrial purposes, with substantial infrastructure that includes several roads, a paved highway up to the front gate of the BFGC properties, plus a power line and substation on the site. BFGC properties include the Bullfrog pit, the adjacent Mystery Hill area, the Montgomery-Shoshone pit.   and the company’s new Paradise Ridge exploration target.

From 1989 to 1999, Barrick Bullfrog, using conventional milling, recovered 2.329 million ounces of gold. The average grade to the mill was 3 g/t, with underground ore averaging over 8 g/t. Barrick used cutoff grades of 0.5 g/t for pits and 3.0 g/t for underground. Its operations ceased in 1999 when reserves were depleted and at a time when gold was trading at significantly less than $300/ oz.

BFGC is not the only outfit that thinks there’s still more gold to be found in region. In October 2018, Coeur Mining put out $90 million to acquire Northern Empire, which has properties in the District (https://ibn.fm/sm5co). And in May this year, AngloGold Ashanti, the world’s third-largest gold mining company, committed $3 million to purchase certain properties in the District from Renaissance Gold (https://ibn.fm/V7O5N). Other companies operating include Kinross Gold, which has staked several hundred claims, and Corvus Gold, which continues to expand its large land and resource positions.

BFGC’s current project resources estimated in 2017 by Tetra Tech were 525,000 oz. of measured and indicated heap leachable gold resources averaging 1.02 g/t and 111,000 oz. of inferred resources at 1.2 g/t. The Tetra estimates were based on a recovery of 72%. However, CEO Beling noted that metallurgical sampling and testing programs during the past two years achieved an average 86% gold recovery.

BFGC’s 2020 drilling program involved 25 holes in total, of which 17 were designed to expand resources and the Bullfrog pit limits toward the northeast in Mystery Hill area. Now, Beling observed, there is enough close-spaced holes to convert most of BFGC’s “inferred resources” to “measured and indicated resources” and expand resource along strike and down dip in this area.

Six holes  were designed and  drilled in the Montgomery-Shoshone area to expand resources and pit limits in this area, which is about one mile to the northeast of the Bullfrog pit. , Hole 22 had 80 ft. of mineralization at 0.54 g/t while Hole 21 had 200 ft. of mineralization at 0.78 g/t. Importantly, the nearest hole from mineral intercept in Hole 22 is approximately 600 ft. to the northeast, thereby providing very good potential for further expansions of mineralization and perhaps the pit.

Although the two holes drilled at the far south end of the Paradise Ridge Target did not intersect mineralization, only about 4% of the area was drill tested while still having good exploration potential for 2,000 meters to the northwest. In summary, BFGC achieved success both in defining the limits of its resources and its pits.

For more information, visit the company’s website at www.BullFrogGold.com.

NOTE TO INVESTORS: The latest news and updates relating to BFGC are available in the company’s newsroom at http://ibn.fm/BFGC

• Surging viewership numbers on online streaming platforms, capacity constraints amongst legacy film studios have led to increased need for new facilities
• A number of new film studios have recently been commissioned, including ones in Montana and Long Island
• The Movie Studio is only major independent film studio in South Florida, placing it in ideal position to benefit from surge in demand for original content production

The Movie Studio (OTC: MVES), an independent Florida-based film studio, is set to benefit as a surge in demand for movie and television content has led to an increased need for film studios. With COVID restrictions across the globe leading to an exponential increase in OTT viewing figures, streaming companies such as Netflix and Disney+ are reporting record growth in their subscriber bases while newcomers including NBCUniversal’s Peacock and AT&T’s HBO Max are racing to develop original content programming which can be used to entice users to their platforms (https://ibn.fm/7b39G).

Parviz Farahzad, a Nassau County-based real estate developer, has recently struck a financing deal to construct a new film studio on Long Island, as demand for new content development and social distancing have led to a newfound need to build outside of the traditional California studio enclaves where films and tv shows have been habitually filmed in the past.

“I am delighted that the IDA is able to assist in bringing a third fully approved NYS sound studio to Nassau County, just as the film and television industry is making its comeback – with major players like HBO, Apple TV, Netflix and NBC all with projects in the works,” said Nassau County Executive Laura Curran.

In a separate deal announced in early September, media company Shadowcast Partners announced that they would build a $20 million studio-grade sound stage for television and film production in Missoula, Montana, describing the soon-to-be-built “Montana Media Hub” as an asset class that’s in high demand but is lacking supply (https://ibn.fm/N9oKT).

“This is really focused on television and film production, but it could also include streaming platforms such as Netflix, Amazon and Apple, or large network and cable giants like Paramount, Warner Brothers and Hallmark,” said Graham. “We think Montana is poised with the right investment to establish a strong new industry in the state due to the MEDIA Act and tax incentives passed last year.”

Based in Fort Lauderdale and founded in 1961, The Movie Studio Inc. is the only major independent film studio located in South Florida. Having previously produced and distributed major motion pictures in the state such as ‘Exposure’, ‘Bad Actress’ and ‘Dancing on the Edge’, The Movie Studio is now engaging in the pre-production of its next film, Cause & Effect, a Miami street movie about the seedy underbelly of South Florida nightlife, and has also begun pre-production on Pegasus, a family movie about a young girl and a horse which is planned to be their “signature film” (https://ibn.fm/XlwOL).

With the demand to produce and film original media content facing challenges from capacity constrained Hollywood studios, The Movie Studio’s unique business model and Florida location has positioned the company to benefit from the wave of growth within the OTT industry.

“The Movie Studio fulfills our objective as we enter the second tier of the digital revolution,” stated MVES president and CEO Gordon Scott Ventures. “We have confidence in the value proposition of the brand and our acceleration into the exploding digital motion picture universe.”

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

• CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer.
• In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit.
• In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation.
• A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade.
• Industry reports estimate that the global brain tumor therapeutics market will reach $2.74 billion in 2023 and $3.4 billion by 2025, up from $2.25 billion in 2019.

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (“API”) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://ibn.fm/QOqjB).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Legal marijuana market set to top more than $90 billion by 2027
• Pac Roots places top priority on developing, delivering finest cannabis genetics
• Optimized farming systems employed in most fertile areas means maximum opportunity for harvest

After experiencing a few roadblocks over the last year, the cannabis sector looks to be picking up speed. In fact, a recent Data Bridge Market Research study reports that the global legal marijuana market should top more than $90 billion by 2027 (https://ibn.fm/UE8Tj). Pac Roots Cannabis (CSE: PACR), a Canadian company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach, has taken strategic steps to be in a strong position as the market heads upward.

For starters, the company is leveraging its expertise in cultivating quality flowers. “Pac Roots is dedicated to delivering the finest cannabis genetics to its consumers, preserving the excellence of its carefully cultivated elite strains while also working to introduce superior new strains,” a recent article spotlighting the company reported (https://ibn.fm/RQHKp). “While some companies may strive to be the largest cannabis grower, Pac Roots believes that the quality of the product is paramount.”

PACR is able to do maintain this strict commitment to quality through a strategic licensing agreement with Phenome One Corp, which gives Pac Roots complete access to one of Canada’s largest live, genetic cannabis libraries (https://ibn.fm/XAG9K). This unparalleled resource allows Pac Roots and Phenome One to develop elite strains with multiple beneficial characteristics. PACR’s extensive catalog features more than 350 tested cultivars, with some 50 qualifying for the super-elite category.

In addition, Pac Roots has carefully chosen superior growing sites, including Rock Creek Farms, located in the South Okanagan Valley in British Columbia. The area, known as the Golden Mile, has even been called the Napa Valley of the North. The 100-acre, premium hemp farm is a joint venture that Pac Roots started with Rock Creek Farms earlier this year after receiving a hemp cultivation license from Health Canada.

Pac Roots has also announced completion of a share purchase agreement of 250 acres of pristine property in the Fraser Valley Regional District of British Columbia. In the agreement, Pac Roots has acquired all of the issued and outstanding shares of 1088070 BC. Ltd., which owns land in one of the most productive and intensively farmed areas in Canada.

Pac Roots works closely with its partners to optimize cultivation through unique proprietary methods, including the use of custom-formulated nutrients made from raw sales; systematic planting of young, hardy cultivars; row compaction and mowing for weed control; and a complex irrigation system that delivers nutrients and spring water directly to each plant.

Pac Roots began operations in 2012 with initial activities directed toward exploration and development of mineral properties in Canada. The company’s mission has evolved through time, and today, PacRoots is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top-quality products. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company’s passion. Genetic variation and stability are the foundation that drives the decision-making for Pac Roots Cannabis Corp.’s business.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027
• Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade
• The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States.
• 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020

Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most significant driver of disease – inflammation. Part of the body’s natural defense system by removing foreign stimuli from the body to begin the healing process, inflammation plays a significant role in a wide range of diseases and ailments, including asthma, arthritis, psoriasis, COVID-19 and more.

Inflammation within the body presents itself in two forms – acute and chronic. The World Health Organization (“WHO”) ranks chronic diseases (like a chronic inflammatory disease) as the most significant risk to human health. The conditions associated with chronic inflammation are anticipated to increase persistently over the next 30 years within the United States.

In 2014, the Rand Corporation estimated that 60% of Americans had at least one chronic condition, 42% had more than one, and 12% of adults had five or more chronic conditions. In 2000, 125 million Americans lived with chronic diseases, and 61 million had more than one (https://ibn.fm/jE8Tw).

180 Life Sciences is devoting its clinical-stage biotechnology research to producing solutions that will help health professionals battle inflammation. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases.

The company’s fibrosis and anti-TNF clinical trials (phase 2b/3) are conducted at the Kennedy Institute within Oxford University and led by Professor Jagdeep Nanchahal and Professor Sir Marc Feldmann. The first results of these trials, addressing four critical areas of inflammation – Dupuytren’s disease, frozen shoulder, post-operative cognitive deficit, and liver fibrosis and nonalcoholic steatohepatitis – are expected in 2021.

180 Life Sciences is also running two preclinical stage trials regarding chronic inflammatory pain (at the Hebrew University in Israel and led by Professor Raphael Mechoulam) and the a7nAChR nicotine receptor and its role in the body’s method of controlling inflammation (at Stanford University and led by Professor Lawrence Steinman and Dr. Jonathan Rothbard).

The company’s work addressing inflammation makes it an attractive investment, as its potential for growth is significant given the size and expansion rate of the anti-inflammatory therapeutics market. According to Allied Market Research, the anti-inflammatory drug therapy market is expected to grow to approximately $106.1 billion annually in 2020 (https://ibn.fm/iC9AZ). From 2015 to 2020, the registered CAGR would be 5.9%. According to Fortune Business Insights, the market is expected to continue growing and generating revenue of $191.42 billion through 2027 (https://ibn.fm/d9Zp4).

In addition, Professor Sir Marc Feldmann, who leads the Fibrosis & Anti-TNF trial, has already developed and marketed an anti-TNF drug (Remicade). He developed this very first anti TNF inhibitor with Dr. James Woody, who was Chief Scientific Officer at Centocor, and will serve as CEO of 180LS. Remicade was the primary driver in the $4.9 billion acquisition of Centocor by Johnson & Johnson in 1998.  Remicade was developed with the Today, Remicade remains one of the bestselling anti-TNF drugs for Johnson & Johnson. The global sales for anti-TNFs in 2016 were $36 billion.

180 Life Sciences Corp. is currently nearing the end of a merger with special purpose acquisition company KBL Merger Corp. IV (NASDAQ: KBLM), which should finalize in Q4 2020. Once the merger has been completed, 180 Life Sciences will be listed on the NASDAQ Capital Market under the ticker symbol ‘ATNF.’ At present, KBL Merger Corp. IV values 180 Life Sciences Corp. at an estimated $175 million, with the acquisition being carried out through share swapping.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

• Streaming sites are among businesses that have seen an uptick in sales during worldwide pandemic
• Content key for companies in streaming space
• The Movie Studio moving forward in space, expanding content and keeping costs down

Not all businesses are struggling through the worldwide pandemic. A recent CompariTech article reported that streaming video is becoming a viable option for a growing number of viewers around the world, resulting in increasing numbers for companies involved in streaming content (https://ibn.fm/wSNni). The Movie Studio (MVES), a vertically integrated motion picture production and distribution company, is looking to become a major player in this star-studded industry, which now has national and international streaming services operating in almost every country.

“While many businesses have struggled due to stay-at-home orders, streaming sites are among the businesses that have seen an uptick in sales,” the article observed. “For example, Netflix added almost 16 million subscribers during the first three months of 2020. It attributed this high number to the fact that people are spending so much more time at home. Disney+ is another big winner, and an uptick in new subscribers pushed it past sister service Hulu in terms of user numbers.”

The article also noted the importance of content, with Netflix reportedly spending more than $17 billion on content in 2020; the company plans to spent $26 billion by 2028. And while content is key, a recent Nielsen Total Audience Report noted that cost, ease of use, and variety are also important streaming-service attributes (https://ibn.fm/t83gv).

Specifically, the report stated that 84% of users rank cost as an extremely or very important attribute when selecting a streaming service. This is closely followed by ease of use (81%), variety or availability of content (79%), streaming and playback quality (77%), and speed of menu selection and content loading (74%).

Aware of these key factors, the Movie Studio is strategically moving forward in the sector. The company is expanding its content by purchasing legacy film libraries — and then upgrading the acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the Internet. In addition, the company is currently in production of three original-content films: “Cause and Effect,” “The Last Warhead” and “Pegasus.”

With a priority on keeping costs down and creativity up, the Movie Studio is establishing a proprietary OTT VOD platform to distribute both its own and aggregated feature film projects, television programming and other media intellectual properties. In addition, the company is pioneering new media content-delivery systems with its digital business model of motion picture distribution as well as its plans to create a direct-server access platform of its content for worldwide distribution. In each effort, the Movie Studio is placing a high premium on accessibility, ease of use, quality of service and functionality.

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES